featured
Carfilzomib, Lenalidomide, and Dexamethasone With Lenalidomide Maintenance as Early Intervention in High-Risk Smoldering Multiple Myeloma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
JAMA Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Carfilzomib, Lenalidomide, and Dexamethasone Followed by Lenalidomide Maintenance for Prevention of Symptomatic Multiple Myeloma in Patients With High-risk Smoldering Myeloma: A Phase 2 Nonrandomized Controlled Trial
JAMA Oncol 2021 Sep 16;[EPub Ahead of Print], D Kazandjian, E Hill, A Dew, C Morrison, J Roswarski, N Korde, M Emanuel, A Petrosyan, M Bhutani, KR Calvo, A Dulau-Florea, M Kwok, MJ Lee, S Lee, L Lindenberg, S Mailankody, E Manasanch, I Maric, E Mena, N Patel, N Tageja, JB Trepel, B Turkbey, HW Wang, W Wang, C Yuan, Y Zhang, R Braylan, P Choyke, M Stetler-Stevenson, SM Steinberg, WD Figg, M Roschewski, O LandgrenFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.